Advance your academic career, collaborate globally, and expand your network— join now !

Ildikó Csóka

Dr. Ildikó Csóka

Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharma...
+ 1

Share Link

Share

Information

Prof. Dr. Ildikó Csóka is an Associate Professor and the Head of the Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged. She obtained her Master in Health Care Management from Semmelweis University, Budapest in 1996 and a Ph.D. from the University of Szeged in 1997. From 2009 to 2011, she completed her specialization in Quality Assurance at the University of Szeged. Her research fields and activities are simple/multiple emulsions-based colloidal structures (micro- and nanospheres, liposomes, SLN, etc.) as targeted drug delivery systems; peptide delivery, dosage form design for alternative delivery routes; regulatory science: "Quality by Design" based dosage form formulation, method developments; Patient Reported Outcome Measures; patient behavior/adherence; drug therapy; and dosage form design relationships.

Research Keywords & Expertise

Biologics
Liposomes
Quality by Design
Regulatory Affairs
Regulatory Science

Fingerprints

28%
Quality by Design
11%
Liposomes
5%
Biologics
5%
Solid Lipid Nanoparticles
5%
polymeric nanoparticles
5%
Regulatory Affairs

Short Biography

Prof. Dr. Ildikó Csóka is an Associate Professor and the Head of the Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged. She obtained her Master in Health Care Management from Semmelweis University, Budapest in 1996 and a Ph.D. from the University of Szeged in 1997. From 2009 to 2011, she completed her specialization in Quality Assurance at the University of Szeged. Her research fields and activities are simple/multiple emulsions-based colloidal structures (micro- and nanospheres, liposomes, SLN, etc.) as targeted drug delivery systems; peptide delivery, dosage form design for alternative delivery routes; regulatory science: "Quality by Design" based dosage form formulation, method developments; Patient Reported Outcome Measures; patient behavior/adherence; drug therapy; and dosage form design relationships.